284 related articles for article (PubMed ID: 33239388)
21. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo.
Kalyuzhniy O; Di Paolo NC; Silvestry M; Hofherr SE; Barry MA; Stewart PL; Shayakhmetov DM
Proc Natl Acad Sci U S A; 2008 Apr; 105(14):5483-8. PubMed ID: 18391209
[TBL] [Abstract][Full Text] [Related]
22. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.
Uusi-Kerttula H; Davies J; Coughlan L; Hulin-Curtis S; Jones R; Hanna L; Chester JD; Parker AL
Oncotarget; 2016 May; 7(19):27926-37. PubMed ID: 27056886
[TBL] [Abstract][Full Text] [Related]
23. Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.
Yu D; Jin C; Leja J; Majdalani N; Nilsson B; Eriksson F; Essand M
J Virol; 2011 Dec; 85(24):13114-23. PubMed ID: 21957304
[TBL] [Abstract][Full Text] [Related]
24. Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases.
Xu W; Zhang Z; Yang Y; Hu Z; Wang CH; Morgan M; Wu Y; Hutten R; Xiao X; Stock S; Guise T; Prabhakar BS; Brendler C; Seth P
Mol Ther; 2014 Aug; 22(8):1504-1517. PubMed ID: 24791939
[TBL] [Abstract][Full Text] [Related]
25. Adenovirus Type 6: Subtle Structural Distinctions from Adenovirus Type 5 Result in Essential Differences in Properties and Perspectives for Gene Therapy.
Romanenko M; Osipov I; Netesov SV; Davydova J
Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683934
[TBL] [Abstract][Full Text] [Related]
26. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
[TBL] [Abstract][Full Text] [Related]
27. Structural insights into the interaction between adenovirus C5 hexon and human lactoferrin.
Dhillon A; Persson BD; Volkov AN; Sülzen H; Kádek A; Pompach P; Kereïche S; Lepšík M; Danskog K; Uetrecht C; Arnberg N; Zoll S
J Virol; 2024 Mar; 98(3):e0157623. PubMed ID: 38323814
[TBL] [Abstract][Full Text] [Related]
28. Refined Capsid Structure of Human Adenovirus D26 at 3.4 Å Resolution.
Reddy VS; Yu X; Barry MA
Viruses; 2022 Feb; 14(2):. PubMed ID: 35216007
[TBL] [Abstract][Full Text] [Related]
29. PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.
Kloos A; Woller N; Gürlevik E; Ureche CI; Niemann J; Armbrecht N; Martin NT; Geffers R; Manns MP; Gerardy-Schahn R; Kühnel F
Cancer Immunol Res; 2015 Jul; 3(7):751-63. PubMed ID: 25701327
[TBL] [Abstract][Full Text] [Related]
30. Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors.
Teigler JE; Penaloza-MacMaster P; Obeng R; Provine NM; Larocca RA; Borducchi EN; Barouch DH
Clin Vaccine Immunol; 2014 Aug; 21(8):1137-44. PubMed ID: 24943382
[TBL] [Abstract][Full Text] [Related]
31. Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions.
Qiu H; Li X; Tian X; Zhou Z; Xing K; Li H; Tang N; Liu W; Bai P; Zhou R
J Virol; 2012 Aug; 86(15):7964-75. PubMed ID: 22623776
[TBL] [Abstract][Full Text] [Related]
32. Influence of chimeric human-bovine fibers on adenoviral uptake by liver cells and the antiviral immune response.
Rogée S; Grellier E; Bernard C; Jouy N; Loyens A; Beauvillain JC; Fender P; Corjon S; Hong SS; Boulanger P; Quesnel B; D'Halluin JC; Colin M
Gene Ther; 2010 Jul; 17(7):880-91. PubMed ID: 20393506
[TBL] [Abstract][Full Text] [Related]
33. Coagulation factor X activates innate immunity to human species C adenovirus.
Doronin K; Flatt JW; Di Paolo NC; Khare R; Kalyuzhniy O; Acchione M; Sumida JP; Ohto U; Shimizu T; Akashi-Takamura S; Miyake K; MacDonald JW; Bammler TK; Beyer RP; Farin FM; Stewart PL; Shayakhmetov DM
Science; 2012 Nov; 338(6108):795-8. PubMed ID: 23019612
[TBL] [Abstract][Full Text] [Related]
34. Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.
Coughlan L; Vallath S; Gros A; Giménez-Alejandre M; Van Rooijen N; Thomas GJ; Baker AH; Cascalló M; Alemany R; Hart IR
Hum Gene Ther; 2012 Sep; 23(9):960-79. PubMed ID: 22708837
[TBL] [Abstract][Full Text] [Related]
35. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses.
Bruder JT; Semenova E; Chen P; Limbach K; Patterson NB; Stefaniak ME; Konovalova S; Thomas C; Hamilton M; King CR; Richie TL; Doolan DL
PLoS One; 2012; 7(4):e33920. PubMed ID: 22496772
[TBL] [Abstract][Full Text] [Related]
36. Recombinant influenza virus carrying human adenovirus epitopes elicits protective immunity in mice.
Yang P; Li T; Liu N; Gu H; Han L; Zhang P; Li Z; Wang Z; Zhang S; Wang X
Antiviral Res; 2015 Sep; 121():145-51. PubMed ID: 26112646
[TBL] [Abstract][Full Text] [Related]
37. In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery.
Coughlan L; Vallath S; Saha A; Flak M; McNeish IA; Vassaux G; Marshall JF; Hart IR; Thomas GJ
J Virol; 2009 Jul; 83(13):6416-28. PubMed ID: 19369326
[TBL] [Abstract][Full Text] [Related]
38. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
39. Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy.
Vragniau C; Hübner JM; Beidler P; Gil S; Saydaminova K; Lu ZZ; Yumul R; Wang H; Richter M; Sova P; Drescher C; Fender P; Lieber A
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077642
[TBL] [Abstract][Full Text] [Related]
40. LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models.
Xu W; Yang Y; Hu Z; Head M; Mangold KA; Sullivan M; Wang E; Saha P; Gulukota K; Helseth DL; Guise T; Prabhkar BS; Kaul K; Schreiber H; Seth P
Hum Gene Ther; 2020 Aug; 31(15-16):863-880. PubMed ID: 32394753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
